newsfilter
← Latest News
Business Wire·

Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments

HOUSTON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented results from two new surveys that examined the effects of peanut allergy on health-related quality of life (HRQoL) among adults and caregivers in the United States. The findings reinforce the need for new treatments in peanut allergy that may reduce concerns related to peanuts, decrease the potential risk of allergic reactions and improve the HRQoL of those impacted by peanut allergy: adult patients, children and their caregivers. These survey results were presented at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.